Another "great mimicker": FDG-PET/CT imaging findings of sarcoid-like reaction.

Ayse Tuba Karagulle Kendi, Emory University
Bruce J Barron, Emory University
Dacian Bonta, Emory University
Raghuveer Halkar, Emory University
Bhawana Rathore, Emory University
David M Schuster, Emory University

Journal Title: BJR Case Reports
Volume: Volume 1, Number 3
Publisher: British Institute of Radiology: BJR Case Reports | 2015, Pages 20150060-20150060
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1259/bjcr.20150060
Permanent URL: https://pid.emory.edu/ark:/25593/tjv42

Final published version: http://dx.doi.org/10.1259/bjcr.20150060

Copyright information:
© 2015 The Authors. Published by the British Institute of Radiology
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed April 20, 2019 7:36 PM EDT
CASE REVIEW

Another “great mimicker”: FDG-PET/CT imaging findings of sarcoid-like reaction

T K KENDI, MD, B J BARRON, MD, D BONTA, MD, R K HALKAR, MD, B RATHORE, MD and D M SCHUSTER, MD

Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA
Veterans Affairs Medical Center, Atlanta, GA, USA
Address correspondence to: Dr Ayse Tuba Karagulle Kendi
E-mail: ayse.kendi@emory.edu

ABSTRACT

Sarcoid-like reaction (SLR) is a cause of non-caseating granulomas in some of the cancer patients with otherwise no signs or symptoms of sarcoidosis. SLR has been described in a variety of solid organ malignancies, including breast and lung cancer. SLR may result in hypermetabolic activity in 18-fludeoxyglucose positron emission tomography (PET)/CT scan, resulting in false positive reporting for malignancy. The purpose of this case series is to expose residents/practising physicians who interpret PET/CT to a series of cases illustrating findings of SLR.

CASE REVIEW

Case 1

The patient was a 63-year-old male with adenocarcinoma of the rectosigmoid junction and multifocal tubular adenoma of the right colon. The patient underwent right hemicolectomy and 6 cycles of folinic acid (also called leucovorin, FA or calcium folinate)/fluorouracil (5FU)/oxaliplatin (FOLFOX).

Findings: Post-therapy positron emission tomography (PET)/CT scan showed bilateral symmetric hilar and mediastinal enlarged lymph nodes with increased 18-fludeoxyglucose (FDG) activity (Figure 1). The maximum standardized uptake value (SUV max) of the subcarinal lymph node was 11.7, SUV max of the right hilar lymph nodes was 10.6 and that of the left hilar lymph nodes was 9. There were no lung abnormalities to suggest active infection or inflammation. Biopsy of one of these lymph nodes was consistent with sarcoid-like reaction (SLR).

Case 2

The patient was a 45-year-old female with multifocal multicentric left breast cancer, mcT2N0M0, Stage 2A, oestrogen receptor/progesterone receptor+, human epidermal growth factor 2(+)$. The patient had chemotherapy followed by left mastectomy and reduction of the right breast. She completed radiation therapy afterwards and started chemotherapy.

Figure 1. Case 1. A 63-year-old male post surgery and chemotherapy for colonic tumour. Post-therapy coronal fused PET/CT (a) and coronal PET (b) show mediastinal (arrow, a,b) and symmetric bilateral hilar hypermetabolic adenopathy (arrowhead, a,b). The biopsy result was consistent with sarcoid-like reaction. PET, positron emission tomography.

Figure 2. A 45-year-old female post therapy for breast cancer. Axial positron emission tomography image (a) and coronal maximum intensity projection image (b) show interval development of symmetric hilar adenopathy with intermediate 18-fludeoxyglucose activity (arrows).
Findings: PET/CT scan after completion of radiation therapy revealed hypermetabolic symmetric hilar lymph nodes (Figure 2). SUV max of the right hilar lymph nodes was 8.6 and SUV max of the left hilar lymph nodes was 8.5. There were no lung findings to suggest active infection. Upon review of the history with the patient’s oncologist, this appearance was accepted as most consistent with SLR. Follow-up PET/CT scan revealed interval resolution of hypermetabolic lymph nodes (Figure 3).

Case 3
A 57-year-old male with non-Hodgkin’s lymphoma presented initially with a left lower extremity swelling. The patient was found to have a large mass in the left iliac wing and was diagnosed with diffuse B-cell lymphoma. The patient underwent 6 cycles of rituximab and Cytoxan (cyclophosphamide)/Adriamycin (hydroxy doxorubicin)/vincristine (Oncovin)/prednisone (also known as CHOP).

Findings: Initial PET/CT showed a lytic hypermetabolic mass in the left iliac wing with left pelvic hypermetabolic adenopathy (Figure 4). Biopsy of the bone lesion revealed diffuse B-cell lymphoma. The first post-treatment PET/CT scan performed 8 months after completion of therapy showed a complete “metabolic” response (Figure 5). The second follow-up PET/CT scan 2 years after completion of therapy demonstrated new mediastinal/hilar hypermetabolic adenopathy (Figure 6). SUV max of the precarinal lymphadenopathy was 18.7, subcarinal lymphadenopathy was 26.3 and that of the right hilar lymph nodes was 24.6. Biopsy of one of these lymph nodes revealed non-caseating granulomatous inflammation. The third follow-up PET/CT scan after 2 years showed new abdominal hypermetabolic adenopathy (Figure 7) with SUV max of 8.7. The last follow-up PET/CT scan after 2 years showed new mediastinal/hilar hypermetabolic adenopathy (Figure 8) with SUV max of 8.7. The last follow-up PET/CT scan after 2 years showed new mediastinal/hilar hypermetabolic adenopathy (Figure 8) with SUV max of 8.7. The last follow-up PET/CT scan after 2 years showed new mediastinal/hilar hypermetabolic adenopathy (Figure 8). The patient did not receive any therapy after the first follow-up PET/CT scan. The second to last follow-up PET/CTs were acquired to monitor SLR-related findings. There was spontaneous resolution of FDG activity of these nodes, thus it was not a treatment-induced tumour response.

DISCUSSION
Pathophysiology of SLR is not completely understood. There are, in general, two forms, localized (around the tumour) and general (distant sites from primary tumour). The localized form of SLR could be from degenerative/necrotic changes within the tumour or adjacent tissues, while the general form may represent a systemic inflammatory response. "Metabolic" response to therapy is often observed in these patients, characterized by a reduction in metabolic activity of the involved nodes. The resolution of this activity without treatment suggests that SLR may not always be a treatment-induced phenomenon.
tumour. The general SLR might be from humoral or T-cell mediated factors, resulting in activation of macrophages.

SLR is more common with patients undergoing restaging PET/CT scan rather than initial staging PET/CT scan.

There are a variety of uptake patterns at PET/CT. The most common patterns are mediastinal nodal and/or symmetric hilar uptake. Other presentation patterns include pulmonary abnormalities, such as pulmonary nodules, ground-glass opacities, regional lymph nodes, liver, spleen or bone marrow uptake.

**LEARNING POINTS**

1. SLR can be seen in a variety of solid-organ malignancies, either at the time of diagnosis or up to several years after.
2. Symmetric mediastinal/hilar FDG activity, unexpected FDG activity in a lymph node, bone or organ in cases with otherwise complete response to therapy should be interpreted carefully for the presence of SLR.
3. The FDG-PET/CT pattern can suggest SLR and should be reported as such.
4. Awareness of SLR will prevent unnecessary biopsy and therapy, but close follow-up is warranted.

**REFERENCES**